WCN26-2182 Inhibition of c-Maf and Chemokine receptors prevents the progression of Fabry Disease nephropathy

Read full text Summarise with VIRAT
Authors: Yuta Mitsuishi, Kensei Taguchi, MAKIKO OGASAWARA, YUYA YAMASHITA, Kei Fukami
Cited by: 0

Summary

No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.

Summarise with VIRAT Free to try with your Science Catalogs account.

Abstract

Fabry disease (FD) is an X-linked genetic disorder caused by deficiency of α-galactosidase A (GLA), a lysosomal hydrolytic enzyme; thus, globotriaosylceramide (Gb3) accumulates in lysosomes, causing visceral organ damage. Kidney injury occurs in approximately 55% of FD patients, which has an impact on mortality. Although enzyme replacement therapy (ERT) has been established in clinics, kidney injury progressed in some cases even after ERT reduced Gb3 accumulation. Furthermore, cardiac and kidney dysfunction appears in female FD patients despite little amount of Gb3 accumulation, suggesting that cytotoxic factors other than Gb3 accumulation might be involved in the progression of FD nephropathy.

Fields of Study & Subjects

Lysosomal Storage Disorders Research Glycogen Storage Diseases and Myoclonus Biomedical Research and Pathophysiology

Publication details

Journal / source
Kidney International Reports
Volume
11
Issue
4
Pages
105800–105800
Publication date
25 March 2026
Language
EN